Titration doses of maridebart cafraglutide

The dosing regimen for maridebart cafraglutide addresses gastrointestinal side effects of GLP-1R agonists by administering the antibody-peptide conjugate at specific time points, effectively promoting weight loss and treating obesity and type 2 diabetes.

WO2026117667A1PCT designated stage Publication Date: 2026-06-04AMGEN INC
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
AMGEN INC
Filing Date
2025-11-26
Publication Date
2026-06-04

Smart Images

  • Figure IMGF000029_0001
    Figure IMGF000029_0001
  • Figure IMGF000030_0001
    Figure IMGF000030_0001
  • Figure IMGF000033_0001
    Figure IMGF000033_0001
Patent Text Reader

Abstract

The present invention relates to methods of treating obesity and obesity-related conditions. The claimed methods can be used to reduce gastrointestinal side-effects associated with administration of GLP-1R agonists. Included also are titrations of maridebart cafraglutide doses.
Need to check novelty before this filing date? Find Prior Art